Medical News

Filed under: Cervical Cancer

Cervarix, an experimental cervical cancer vaccine made by British pharmaceutical firm GlaxoSmithKline, had somewhat of an important public milestone this week, as The Lancet published information on the vaccine being 90 percent effective in preventing precancerous cervical lesions.

These results do indeed confirm previous data on the effectiveness of Cervarix, and as such, the stage is set for the vaccine to become a big hit with cervical cancer sufferers and women who have just been diagnosed.

Australia has already approved Cervarix, and expected approval for Europe is slated to happen this year in the second half. For a U.S. release, we’ll have to wait until sometime in 2008. That is, if is is approved here.

Read | Permalink | Email this | Linking Blogs | Comments

Original post by Brian White

Filed under: Cervical Cancer

Cervarix, an experimental cervical cancer vaccine made by British pharmaceutical firm GlaxoSmithKline, had somewhat of an important public milestone this week, as The Lancet published information on the vaccine being 90 percent effective in preventing precancerous cervical lesions.

These results do indeed confirm previous data on the effectiveness of Cervarix, and as such, the stage is set for the vaccine to become a big hit with cervical cancer sufferers and women who have just been diagnosed.

Australia has already approved Cervarix, and expected approval for Europe is slated to happen this year in the second half. For a U.S. release, we’ll have to wait until sometime in 2008. That is, if is is approved here.

Read | Permalink | Email this | Linking Blogs | Comments

Original post by Brian White